This reality also could impact stock performance. That said, even with positive results in a relatively small sample size, there is no guarantee that Pfizer’s vaccine will be approved or will work on a wide-scale. Conversely, work-from-home stocks like Peloton could suffer as more people may opt to exercise in a gym, rather than inside their home. Here are some other sectors to watch for:Įssentially, any business that could thrive when in-person activity increases is a potential winner in this scenario. Other stocks outside the healthcare sector could benefit with the approval of a potential vaccine. While a 20% stock price drop is relatively small against the backdrop of year-to-date performance, it could be a sign of further downward pressure on Zoom’s share price if the vaccine receives regulatory and marketing approval.
The stock opened at 65 and closed at 62 and gave a 72 percent gain from the listing date. Their forecasts range from 9000 to 40000. If more people return to in-person work or if social distancing rules are eased, or both, fewer people could use Zoom. The average ZOOM Technologies stock forecast 2025 represents a 84381 increase from the last price of 999999974737875E-5. A potential vaccine, if effective and if widely distributed, implies that Zoom’s growth and user base could slow.
0 kommentar(er)
